Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAVATAK in Advanced Melanoma
NCT01227551Phase 2Completed
- Sponsor
- Viralytics Ltd
- Start
- Dec 2011
- Primary completion
- Apr 2016
- Modality
- Oncolytic Viruses, Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of coxsackievirus a21 in Malignant Melanoma (MM), sponsored by Viralytics Ltd. Primary endpoint: Immune-related Progression-Free Survival at 6 months. Started Dec 2011; status: completed.
02
Drugs
coxsackievirus a21
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT01227551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01227551.